PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Status:
Recruiting
Trial end date:
2024-12-26
Target enrollment:
Participant gender:
Summary
A Phase 1 Dose Escalation and Expanded Cohort Study Of PF-06821497 In The Treatment Of Adult
Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant
Prostate Cancer (CRPC) And Follicular Lymphoma (FL).